Status:
COMPLETED
A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis
Lead Sponsor:
Zhongshan Ophthalmic Center, Sun Yat-sen University
Conditions:
Vernal Keratoconjunctivitis
Eligibility:
All Genders
5+ years
Phase:
PHASE4
Brief Summary
To evaluate the efficacy and safety of 0.1% tacrolimus combined with loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) in vernal keratoconjunctivitis (VKC) patients resistant to conventional treatment...
Eligibility Criteria
Inclusion
- vernal keratoconjunctivitis patients resistant to conventional treatments
Exclusion
- Patients diagnosed with other coexisting eye disease; with a confirmed or possible pregnancy; younger than 5 years old; had presence of systemic diseases other than coexisting allergic rhinitis, asthma, and atopic dermatitis; reported hypersensitivity to tacrolimus
Key Trial Info
Start Date :
November 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03464435
Start Date
November 1 2016
End Date
February 1 2018
Last Update
March 14 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.